Wegovy and increased appetite: what it means, and when to act

You inject on Sunday. By Thursday, hunger is back. Here's why.

Semaglutide's plasma concentration rises after each injection, peaks within a day or two, then gradually falls before the next dose. For most people this cycle is smooth enough that appetite suppression stays consistent across the week. For others, particularly in the earlier months of treatment or at lower starting doses, the trough before the next injection is noticeable. Hunger returns, sometimes sharply, in the final day or two of the seven-day window.

This is not the medicine failing. It is a pharmacokinetic reality. Semaglutide's half-life is roughly seven days, which is why once-weekly dosing works at all, but it also means that levels at day six or seven are lower than they were at day two. The clinical trials that produced Wegovy's evidence base used strict weekly schedules for exactly this reason. Keeping your injection day consistent matters more than most people realise.

You can read more about how Wegovy's mechanism interacts with appetite on our page on whether Wegovy decreases appetite, which covers the GLP-1 pathway in more detail. The Wegovy doses overview also explains how appetite suppression typically strengthens as titration progresses.

Other things that quietly reduce how much semaglutide you absorb

A question our prescribers hear most weeks is: "I'm doing everything right, so why is my appetite back?" The honest answer is that several variables affect how much active medicine reaches your system, and not all of them are obvious.

Storage is one. Wegovy pens must be refrigerated between 2°C and 8°C. A pen left at room temperature beyond the window described in the Patient Information Leaflet degrades, not visibly, but in terms of potency. If your pen has been warm for longer than the leaflet allows, absorption on that dose will be lower than expected. Always check the leaflet for the exact room-temperature limit; the number varies and the leaflet is the authoritative source.

Injection technique is another. Air bubbles in the pen, injecting into scar tissue at a site you have used repeatedly, or pulling the pen away too quickly can all reduce how much medicine is delivered. Rotating between your abdomen, thigh, and upper arm helps. If you have been using the same spot for weeks, switching site is worth trying before assuming anything more complex is happening.

Gastrointestinal illness can also reduce absorption during the acute phase. If you had a stomach bug around the time of an injection, more medicine may have passed through before it could be fully absorbed. Your prescriber can advise whether a repeat injection is appropriate in those circumstances, do not make that call without clinical input.

The guide to Wegovy dose increases covers what typically happens to appetite as the titration schedule progresses, which is useful context here.

When a return of appetite signals something worth investigating

Transient hunger in the days before your next injection is common and usually resolves once you are at a higher maintenance dose. Persistent increased appetite that does not improve across several weeks, or that arrives suddenly after a period of good suppression, is a different matter.

Sudden changes in appetite, especially if accompanied by other symptoms, should always be discussed with a clinician. The NHS medicines page for semaglutide describes the side-effect profile and the circumstances under which you should contact a healthcare professional promptly. If you are also noticing any changes in heart rate, it is worth reading about heart rate changes on Wegovy separately, since that is a distinct consideration your prescriber should know about.

A more gradual return of hunger over several months, sometimes called "weight loss plateau" in clinical contexts, is also documented in longer-term semaglutide use. NICE's appraisal of semaglutide for weight management notes that continuing treatment beyond six months without meaningful progress should prompt a clinical review. That review might result in a dose increase, a reassessment of lifestyle factors, or a discussion about whether the treatment is still the right fit. The guidance is available in NICE technology appraisal TA875.

Cost is sometimes a factor in whether people stay on their current dose or explore alternatives. If that is part of the picture for you, the Wegovy cost page sets out what private treatment typically involves.

What your prescriber can actually do about it

Increased appetite is clinical information. It tells your prescriber something useful: the current dose may not be fully suppressing hunger for you, the injection technique or storage may need reviewing, or your titration schedule might benefit from adjustment.

What a prescriber cannot do is make those assessments without knowing. If you are managing a return of hunger alone and adjusting your eating without flagging it, the opportunity for a clinical response is lost. At nume (at a GPhC-registered pharmacy like ours, where every repeat is reviewed before dispensing) reporting a change in appetite is part of the ongoing clinical conversation, not a reason to be concerned about raising your hand.

The broader Wegovy treatment page gives a full picture of how the medicine is managed from the first dose onwards. If you have questions about treatment options generally, starting a free consultation is the right next step, a GPhC-registered prescriber will review your situation the same day and can advise on whether your current approach needs revisiting.